Last reviewed · How we verify
Immunomonitoring
Immunomonitoring is a Biologic drug developed by University Hospital, Grenoble. It is currently in Phase 2 development.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Immunomonitoring |
|---|---|
| Sponsor | University Hospital, Grenoble |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Role of RNA Metabolism Alterations in Persistent Immune Dysfunction After Sepsis
- CAR-T Immunomonitoring in Multiple Myeloma (CART I5M) (NA)
- Innate Immune Response Monitoring Via Monocyte HLA-DR in Severe Intra-abdominal Infections at Risk of Fungal Infection
- Blood Draw Study for Liver Transplant Patients
- TocilizuMab discontinuAtion in GIant Cell Arteritis (PHASE3)
- MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial (PHASE3)
- Immunomonitoring of Mold Invasive Infections
- Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Immunomonitoring CI brief — competitive landscape report
- Immunomonitoring updates RSS · CI watch RSS
- University Hospital, Grenoble portfolio CI
Frequently asked questions about Immunomonitoring
What is Immunomonitoring?
Who makes Immunomonitoring?
What development phase is Immunomonitoring in?
Related
- Manufacturer: University Hospital, Grenoble — full pipeline
- Therapeutic area: All drugs in Immunology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing